Overview: ASCA IgA TestIntroduction: The ASCA IgA Test detects IgA antibodies to Saccharomyces cerevisiae, linked to inflammatory bowel diseases like Crohn's, causing abdominal pain or diarrhea. Following 2023 AGA guidelines, it uses an immunoassay for high specificity, aiding in autoimmune screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected Crohn's disease.
Other Names: Anti-Saccharomyces Cerevisiae IgA Assay, Crohn's Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: ASCA testing began in the 1990s with IBD research. Immunoassays emerged in the 2000s, and by the 2010s, high-sensitivity assays improved Crohn's diagnosis.
Purpose: Diagnoses inflammatory bowel diseases like Crohn's, guides treatment, and monitors disease activity in patients with abdominal pain or diarrhea.
Test Parameters: 1. Anti Saccharomyces Cerevisiae IgA
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like abdominal pain or diarrhea, and list medications like immunosuppressants.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document gastrointestinal symptoms, IBD history, or family history of Crohn's disease. Include current medications, especially immunosuppressants or biologics.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for immunosuppressive therapy.
Procedural Considerations: Uses an immunoassay to measure ASCA IgA antibodies. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Immunosuppressants may suppress antibody levels, causing false negatives. Hemolysis or improper storage can degrade samples.
Clinical Significance: Positive ASCA IgA results suggest Crohn's disease, prompting biologics or surgery. Negative results may require ASCA IgG testing.
Specialist Consultation: Consult a gastroenterologist for result interpretation. An IBD specialist referral is advised for complex cases.
Additional Supporting Tests: ASCA IgG test, fecal calprotectin, or colonoscopy to confirm Crohn's disease or assess disease activity.
Test Limitations: False positives may occur with other gastrointestinal conditions. Results require clinical correlation with imaging or biopsy.
References: AGA Crohn's Guidelines, 2023; Gastroenterology, Lichtenstein GR, 2022.
